Heron Therapeutics, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 126
- Market Cap
- $292.7M
- Website
- http://www.herontx.com
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06109415
- Locations
- πΊπΈ
First Surgical Hospital, Bellaire, Texas, United States
πΊπΈLegent Orthopedic Hospital, Carrollton, Texas, United States
πΊπΈJBR Clinical Research, Salt Lake City, Utah, United States
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06109428
- Locations
- πΊπΈ
Endeavor Clinical Trials, LLC, San Antonio, Texas, United States
πΊπΈFirst Surgical Hospital, Bellaire, Texas, United States
Safety Study of Repeat Doses of SUSTOL in Adults
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT05434663
- Locations
- πΊπΈ
Gabrail Cancer Center Research, Canton, Ohio, United States
πΊπΈHattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.
- Conditions
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT05109312
- Locations
- πΊπΈ
Endeavor Clinical Trials, LLC, San Antonio, Texas, United States
πΊπΈFirst Surgical Hospital, Bellaire, Texas, United States
πΊπΈLegent Orthopedic Hospital, Carrollton, Texas, United States
HTX-011 in Spinal Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT04911062
- Locations
- πΊπΈ
South Texas Spine & Surgical Center, San Antonio, Texas, United States
πΊπΈM3 Emerging Medical Research, LLC, Durham, North Carolina, United States
πΊπΈAustin Neurosurgeons, Austin, Texas, United States
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT04470622
- Locations
- πΊπΈ
Helen Keller Hospital, Sheffield, Alabama, United States
πΊπΈUniversity of California, Irvine Medical Center, Orange, California, United States
πΊπΈYale University School of Medicine, New Haven, Connecticut, United States
Dose-Escalation Study of HTX-034 Following Bunionectomy
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 73
- Registration Number
- NCT04398329
- Locations
- πΊπΈ
Endeavor Clinical Trials, LLC, San Antonio, Texas, United States
πΊπΈArizona Research Center, Phoenix, Arizona, United States
πΊπΈJBR Clinical Research, Salt Lake City, Utah, United States
Extended Delivery of Bupivacaine Study in Herniorrhaphy
- Conditions
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT04102267
- Locations
- πΊπΈ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 116
- Registration Number
- NCT03974932
- Locations
- πΊπΈ
Endeavor Clinical Trials, LLC., San Antonio, Texas, United States
πΊπΈHelen Keller Hospital, Sheffield, Alabama, United States
πΊπΈPhoenix Clinical Research, LLC, Tamarac, Florida, United States
HTX-011 Administration Study in Planned Caesarean Section Procedure
- Conditions
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT03955211
- Locations
- πΊπΈ
Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States
πΊπΈUPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
πΊπΈHelen Keller Hospital, Sheffield, Alabama, United States